22:16 , Aug 16, 2019 |  BioCentury  |  Finance

Chinese investment in U.S. biotechs to slow further

Chinese VCs say the slowing of investments into U.S. biotechs is likely to get worse before it gets better. In addition to continued CFIUS concerns and the ongoing trade war, capital inflows to Chinese life...
12:40 , Aug 12, 2019 |  BioCentury  |  Finance

Chipscreen sets high standard in Shanghai debut

Chipscreen became the first biopharma to begin trading on Shanghai’s STAR market this week, and the strength of its debut could entice companies sitting on the sidelines to choose a mainland listing over one in...
23:46 , Aug 5, 2019 |  BC Extra  |  Financial News

Aug. 5 Financial Quick Takes: Biotech tumbles with broader markets; plus Exo, 3-V and more

Biotech stocks take a hit  U.S. biotech stocks fell in line with the broader markets Monday, with the NASDAQ Composite, NYSE Arca Biotechnology Index (BTK), SPDR S&P Biotech ETF (XBI) and BioCentury 100 each losing...
01:37 , Jun 28, 2019 |  BC Innovations  |  Product Development

How Array stayed alive long enough to grow up

Array’s 21-year journey as an independent platform company, culminating in an $11.4 billion buyout, required shifting focus from research to development and back again. The acquisition sends a message that developing focused expertise and sticking...
18:56 , Jun 17, 2019 |  BC Extra  |  Company News

Array takeout buoys biotechs, strengthens Pfizer in targeted oncology

Public biotechs got a boost Monday on the strength of Pfizer's $11.4 billion buyout of Array, signaling that continued M&A interest in the sector can help reverse the loss in momentum that has led to...
23:33 , Apr 19, 2019 |  BioCentury  |  Finance

Hope for China’s academic spinouts

Peking University spinout Hope Medicine is one of the latest examples of a trend that sees academics from Chinese universities increasingly taking top roles in a biotech sector traditionally led by MNC veterans. The start-up...
00:16 , Apr 6, 2019 |  BioCentury  |  Finance

Room to rally in 2Q

Strong small and mid-cap performance coupled with robust M&A has brought the sector back from 4Q18 correction territory, and chances are good for the momentum to continue given the ample capital ready to be recycled...
20:30 , Mar 1, 2019 |  BC Extra  |  Company News

Ex-Merck China R&D head joins Ascletis as CMO

Antiviral and cancer company Ascletis Pharma Inc. (HKSE:1672) hired Zhengqing Li as CMO and president of R&D Greater China. He was global VP of MSD China and general manager of the Merck & Co. Inc....
02:40 , Feb 28, 2019 |  BC Week In Review  |  Financial News

CStone raises $285M in Hong Kong IPO

CStone Pharmaceuticals Co. Ltd. (HKSE:2616) priced its IPO on the Hong Kong stock exchange Feb. 25, raising HK$2.2 billion (US$285 million). The oncology company rose HK$0.86 to HK$12.86 in its first day of trading Feb....
15:01 , Feb 26, 2019 |  BC Extra  |  Financial News

First-day gain for CStone on Hong Kong exchange

CStone Pharmaceuticals Co. Ltd. (HKSE:2616) rose HK$0.86 to HK$12.86 in its first day of trading Tuesday after raising HK$2.2 billion ($285 million) in its IPO. The oncology company priced the offering early Monday near the...